Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154670 · ClinicalTrials.gov registry record · Phase 1
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
A Phase 1 study of Healthy and Renal Insufficiency, sponsored by Ensoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT04154670: Completed Phase 1 study of Healthy and Renal Insufficiency, sponsored by Ensoma.
NCT04154670 is a Phase 1 study of Healthy and Renal Insufficiency that has completed, run by Ensoma. The registered enrollment target is 23 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04154670, a Phase 1 study of Healthy and Renal Insufficiency, has completed, sponsored by Ensoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).
Primary Outcome
Investigate area under the curve (AUC)
Conditions Studied
Interventions
- BIOLOGICAL MGTA-145
Study Locations (2)
Florida
- Orlando Clinical Research Center (OCRC) - Orlando
Tennessee
- Alliance for Multispeciality Research (AMR) Formerly New Orleans Center for Clinical Research (NOCCR) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2020-03-24 |
| Phase | Phase 1 |
What the finished NCT04154670 record still lists
NCT04154670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which MGTA-145 is the first listed.
NCT04154670 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04154670 about?
NCT04154670 is a clinical study titled "Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment". This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).
What is the current status of trial NCT04154670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-11-07. Estimated completion is 2020-03-24.
What conditions does trial NCT04154670 study?
This clinical trial studies the following conditions: Healthy, Renal Insufficiency.
What interventions are being tested in trial NCT04154670?
The interventions under investigation include: MGTA-145 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04154670?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04154670 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04154670's enrollment target sits among peer trials
23 838th of 1090 higher than 248 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI